A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair (ATLAS)
Primary Purpose
Hernia, Ventral, Incisional Hernia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Phasix™ ST
Sponsored by
About this trial
This is an interventional treatment trial for Hernia, Ventral
Eligibility Criteria
Inclusion Criteria:
- Subject must be 18 years of age or older
- Subject must be willing to give written informed consent
- Subject must be diagnosed with ventral or abdominal incisional hernia
- Subject must be willing to undergo laparoscopic hernia repair using intraabdominal placement (with or without Component Separation Technique (CST))
- Surgeon must be able to fully close the hernia defect. Defect closure is defined as complete reapproximation of fascial edges, leaving no gap. Since the safety and effectiveness of Phasix™ ST Mesh in bridging repairs has not been evaluated or established, the defect should be closed prior to mesh use.
- Subject is expected to meet the criteria for a Class I wound
Subjects must have 1 or more of the following pre-study conditions:
- Body Mass Index (BMI) between 30-40 kg/m2, inclusive
- Active smoker (including if attempts to quit smoking within two weeks of surgery have failed and the patient is still an active smoker at the time of surgery)
- COPD presence on patient self-report
- Diabetes mellitus (if yes, diagnosis to be confirmed via medical records or laboratory results according to 2014 Joslin Clinical Guideline for Adults with Diabetes)(Appendix 5)
- Immunosuppression
- Coronary Artery Disease
- Chronic corticosteroid use: greater than 6 months systemic use
- Serum albumin less than 3.4 g/dL
- Advanced age: 75 years or older
- Renal insufficiency, defined as serum creatinine concentration ≥2.5 mg/dL
Exclusion Criteria:
- Subject has had 4 or more previous hernia repairs (of the index hernia)
- Subject's hernia is > 350 cm2
- Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible
- Subject has intact permanent mesh adjacent to the current hernia to be repaired
- Preperitoneal placement of mesh
- The subject is known to have a collagen disorder
- The subject has peritonitis
- The subject is on or suspected to be placed on chemotherapy medications during any part of the study
- The subject's Body Mass Index (BMI) is > 40 kg/m2
- The subject has cirrhosis of the liver and/or ascites
- Subject is American Society of Anesthesiology Class 4 or 5
- Subject has a life expectancy of less than 2 years at the time of enrollment
- Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
- Subject has a surgical wound classified as Class II (Clean-Contaminated), Class III (Contaminated) or Class IV (Dirty-Contaminated)
- Subject has an active or latent systemic infection
- Patient has a contraindication to placement of mesh
- Subject requires surgical bridge repair as the sole repair
- Subject is pregnant or has plans to become pregnant during the study period
- Subject has enrolled in another interventional clinical study within the last 30 days
- Subject is part of the site personnel directly involved with this study
- Subject has a known allergy to the test device or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate should be avoided).
Sites / Locations
- Yale-New Haven Medical Center
- Florida Hospital
- Emory University
- Memorial Health University Medical Center
- Via-Christi Hospital
- Georgetown Community Hospital
- University of Kentucky Medical Center
- Our Lady of the Lake Regional Medical Center
- Washington University
- Methodist Hospital
- New Hanover Regional Medical Center
- Legacy Emanuel Hospital
- Hershey Penn State Medical Center
- Carilion Clinic
- Overlake Hospital
- University of Wisconsin
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Phasix™ ST
Arm Description
Subjects treated with Phasix™ ST mesh
Outcomes
Primary Outcome Measures
Surgical Site Occurrence Rate
Proportion of subjects with Surgical Site Occurrences(SSO), which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 45 days.
Secondary Outcome Measures
Surgical Site Occurrence Rate
Number of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months.
Hernia Recurrence Rate
Proportion of subjects with hernia recurrence. Hernia recurrence rates will be assessed by physical examination (or if standard of care via CT/MRI or ultrasonography) at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure.
Pain Visual Analog Scale
Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 24-month through follow up. Scores are measured on a 10.0 cm line, scores range from 0 to 10, higher values correspond with higher pain perception. The outcome measure is presented as the absolute difference between the pain perception at Baseline and the pain perception at 24-month follow up.
Device-related Adverse Event Incidence
Proportion of subjects with Investigator-determined device-related adverse events
Rate of Reoperation Due to Index Hernia Repair
Rate of reoperation due to the index hernia repair
Change in Carolinas Comfort Scale
Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is the average across the domains. The Total CCS Score ranges from 0-5 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties.
Absolute values of the Total CCS Score at Baseline, 1-Month follow-up, at 3-Month follow-up, at 6-Month follow-up, at 12-Month follow-up, at 18-Month follow-up, and at 24-Month follow up are reported.
The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results.
Change in SF(Short-form)-12
The Short Form (SF)-12 version 2 (v2) is a multi-purpose, twelve item health survey that measures seven domains of health: general health, physical functioning, role limitations due to physical health (role-physical), role limitations due to emotional problems (role-emotional), bodily pain, vitality and mental health and social functioning. The SF-12v2 yields scale scores for each of these seven health domains, and two summary measures of physical and mental health: the physical component summary (PCS) and mental component summary (MCS). The scores range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
Absolute values of the PCS and MCS scores at Baseline, 1-Month follow-up, at 3-Month follow-up, at 6-Month follow-up, at 12-Month follow-up, at 18-Month follow-up, and at 24-Month follow up are reported.
Surgical Procedure Time as Measured From Incision to Closure
Surgical procedure time as measured from incision to closure (skin to skin)
Length of Hospital Stay
Number of days admitted to the hospital for index surgery
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02712398
Brief Title
A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair
Acronym
ATLAS
Official Title
A Prospective, Multi-center Trial of a Long-term Bio-Absorbable Mesh With Sepra Technology in Challenging Laparoscopic Ventral or Incisional Hernia Repair
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
November 15, 2019 (Actual)
Study Completion Date
November 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
C. R. Bard
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ ST in subjects receiving laparoscopic ventral or incisional hernia repair at high risk for surgical site occurrence (SSO).
Detailed Description
Subjects at high risk are defined as having 1 or more of the following co-morbid conditions: body mass index (BMI) between 30-40 kg/m2, inclusive, active smokers, chronic obstructive pulmonary disease (COPD), diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, low pre-operative serum albumin, advanced age, or renal insufficiency.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hernia, Ventral, Incisional Hernia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Phasix™ ST
Arm Type
Experimental
Arm Description
Subjects treated with Phasix™ ST mesh
Intervention Type
Device
Intervention Name(s)
Phasix™ ST
Intervention Description
Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
Primary Outcome Measure Information:
Title
Surgical Site Occurrence Rate
Description
Proportion of subjects with Surgical Site Occurrences(SSO), which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 45 days.
Time Frame
45 Days
Secondary Outcome Measure Information:
Title
Surgical Site Occurrence Rate
Description
Number of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months.
Time Frame
3 months
Title
Hernia Recurrence Rate
Description
Proportion of subjects with hernia recurrence. Hernia recurrence rates will be assessed by physical examination (or if standard of care via CT/MRI or ultrasonography) at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure.
Time Frame
24 Months
Title
Pain Visual Analog Scale
Description
Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 24-month through follow up. Scores are measured on a 10.0 cm line, scores range from 0 to 10, higher values correspond with higher pain perception. The outcome measure is presented as the absolute difference between the pain perception at Baseline and the pain perception at 24-month follow up.
Time Frame
24 Months
Title
Device-related Adverse Event Incidence
Description
Proportion of subjects with Investigator-determined device-related adverse events
Time Frame
24 Months
Title
Rate of Reoperation Due to Index Hernia Repair
Description
Rate of reoperation due to the index hernia repair
Time Frame
24 Months
Title
Change in Carolinas Comfort Scale
Description
Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is the average across the domains. The Total CCS Score ranges from 0-5 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties.
Absolute values of the Total CCS Score at Baseline, 1-Month follow-up, at 3-Month follow-up, at 6-Month follow-up, at 12-Month follow-up, at 18-Month follow-up, and at 24-Month follow up are reported.
The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results.
Time Frame
24 Months
Title
Change in SF(Short-form)-12
Description
The Short Form (SF)-12 version 2 (v2) is a multi-purpose, twelve item health survey that measures seven domains of health: general health, physical functioning, role limitations due to physical health (role-physical), role limitations due to emotional problems (role-emotional), bodily pain, vitality and mental health and social functioning. The SF-12v2 yields scale scores for each of these seven health domains, and two summary measures of physical and mental health: the physical component summary (PCS) and mental component summary (MCS). The scores range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
Absolute values of the PCS and MCS scores at Baseline, 1-Month follow-up, at 3-Month follow-up, at 6-Month follow-up, at 12-Month follow-up, at 18-Month follow-up, and at 24-Month follow up are reported.
Time Frame
24 Months
Title
Surgical Procedure Time as Measured From Incision to Closure
Description
Surgical procedure time as measured from incision to closure (skin to skin)
Time Frame
During Procedure, up to 243 minutes
Title
Length of Hospital Stay
Description
Number of days admitted to the hospital for index surgery
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject must be 18 years of age or older
Subject must be willing to give written informed consent
Subject must be diagnosed with ventral or abdominal incisional hernia
Subject must be willing to undergo laparoscopic hernia repair using intraabdominal placement (with or without Component Separation Technique (CST))
Surgeon must be able to fully close the hernia defect. Defect closure is defined as complete reapproximation of fascial edges, leaving no gap. Since the safety and effectiveness of Phasix™ ST Mesh in bridging repairs has not been evaluated or established, the defect should be closed prior to mesh use.
Subject is expected to meet the criteria for a Class I wound
Subjects must have 1 or more of the following pre-study conditions:
Body Mass Index (BMI) between 30-40 kg/m2, inclusive
Active smoker (including if attempts to quit smoking within two weeks of surgery have failed and the patient is still an active smoker at the time of surgery)
COPD presence on patient self-report
Diabetes mellitus (if yes, diagnosis to be confirmed via medical records or laboratory results according to 2014 Joslin Clinical Guideline for Adults with Diabetes)(Appendix 5)
Immunosuppression
Coronary Artery Disease
Chronic corticosteroid use: greater than 6 months systemic use
Serum albumin less than 3.4 g/dL
Advanced age: 75 years or older
Renal insufficiency, defined as serum creatinine concentration ≥2.5 mg/dL
Exclusion Criteria:
Subject has had 4 or more previous hernia repairs (of the index hernia)
Subject's hernia is > 350 cm2
Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible
Subject has intact permanent mesh adjacent to the current hernia to be repaired
Preperitoneal placement of mesh
The subject is known to have a collagen disorder
The subject has peritonitis
The subject is on or suspected to be placed on chemotherapy medications during any part of the study
The subject's Body Mass Index (BMI) is > 40 kg/m2
The subject has cirrhosis of the liver and/or ascites
Subject is American Society of Anesthesiology Class 4 or 5
Subject has a life expectancy of less than 2 years at the time of enrollment
Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
Subject has a surgical wound classified as Class II (Clean-Contaminated), Class III (Contaminated) or Class IV (Dirty-Contaminated)
Subject has an active or latent systemic infection
Patient has a contraindication to placement of mesh
Subject requires surgical bridge repair as the sole repair
Subject is pregnant or has plans to become pregnant during the study period
Subject has enrolled in another interventional clinical study within the last 30 days
Subject is part of the site personnel directly involved with this study
Subject has a known allergy to the test device or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate should be avoided).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Hope, MD
Organizational Affiliation
New Hanover Regional Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale-New Haven Medical Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
Florida Hospital
City
Celebration
State/Province
Florida
ZIP/Postal Code
34747
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Memorial Health University Medical Center
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31404
Country
United States
Facility Name
Via-Christi Hospital
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67214
Country
United States
Facility Name
Georgetown Community Hospital
City
Georgetown
State/Province
Kentucky
ZIP/Postal Code
40324
Country
United States
Facility Name
University of Kentucky Medical Center
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Facility Name
Our Lady of the Lake Regional Medical Center
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Methodist Hospital
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
Facility Name
New Hanover Regional Medical Center
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Legacy Emanuel Hospital
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Facility Name
Hershey Penn State Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
Carilion Clinic
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24013
Country
United States
Facility Name
Overlake Hospital
City
Bellevue
State/Province
Washington
ZIP/Postal Code
98004
Country
United States
Facility Name
University of Wisconsin
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair
We'll reach out to this number within 24 hrs